Following women's heart health after a first pregnancy
Follows women who had a first pregnancy to study heart disease over time.
Plain-language title generated from the registry record
Registry title: Continuation of the nuMoM2b Heart Health Study
Key facts
- Where
- Chicago, Cleveland, Indianapolis, Murray, New York, Newark, Ogden, Orange, Philadelphia, Pittsburgh, Provo, and Salt Lake City, United StatesSee the 14 sites
Where in United States
- Northwestern UniversityChicago, United StatesNo longer taking part
- Case Western Reserve University/The MetroHealth SystemCleveland, United StatesNo longer taking part
- Indiana UniversityIndianapolis, United StatesNo longer taking part
- Intermountain Medical CenterMurray, United StatesNo longer taking part
- Columbia University Medical CenterNew York, United StatesNo longer taking part
- Christiana Care Health ServicesNewark, United StatesNo longer taking part
- McKay-Dee HospitalOgden, United StatesNo longer taking part
- University of California Irvine Medical CenterOrange, United StatesNo longer taking part
- Hospital of the University of PennsylvaniaPhiladelphia, United StatesNo longer taking part
- Pennsylvania HospitalPhiladelphia, United StatesNo longer taking part
- Magee Womens Research InstitutePittsburgh, United StatesNo longer taking part
- Utah Valley HospitalProvo, United StatesNo longer taking part
- LDS HospitalSalt Lake City, United StatesNo longer taking part
- University of UtahSalt Lake City, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- RTI International
- Trial code
- NCT05472597
- Record updated
- 1 July 2026
- Original description
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in U.S. women at all ages, and large knowledge gaps exist in CVD predictive and preventative strategies for women. The nuMoM2b Heart Health Study (nuMoM2b-HHS) has followed a demographically diverse cohort of women enrolled and richly phenotyped during their first pregnancy, with data and biospecimens prospectively collected for up to 7 years thereafter. The overarching scientific goal of this study is to define the relationship between adverse pregnancy outcomes (APOs) and CVD to optimize CVD prediction, prevention, and treatment strategies for women. Continued follow-up of this observational cohort, building on a foundation of existing high-quality data, biospecimens, and administrative structures with a robust framework for ancillary study development and implementation, provides a unique opportunity to address knowledge gaps regarding the early mechanisms and trajectory of CVD in women.Read full original descriptionShow less
Continuation of the nuMoM2b Heart Health Study
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in U.S. women at all ages, and large knowledge gaps exist in CVD predictive and preventative strategies for women. The nuMoM2b Heart Health Study (nuMoM2b-HHS) has followed a demographically diverse cohort of women enrolled and richly phenotyped during their first pregnancy, with data and biospecimens prospectively collected for up to 7 years thereafter. The overarching scientific goal of this study is to define the relationship between adverse pregnancy outcomes (APOs) and CVD to optimize CVD prediction, prevention, and treatment strategies for women. Continued follow-up of this observational cohort, building on a foundation of existing high-quality data, biospecimens, and administrative structures with a robust framework for ancillary study development and implementation, provides a unique opportunity to address knowledge gaps regarding the early mechanisms and trajectory of CVD in women.
Inclusion: Completed one or more interval contacts during the nuMoM2b Heart Health Study; Able to speak or read in English or Spanish; Completed one or more interval contacts during the nuMoM2b Heart Health Study; At least 18 years of age; Self-report of at least 3 months postpartum from any subsequent pregnancy; Provision of signed informed consent for the HHS2 study visit; Able to speak or read English or Spanish.
Exclusion: Withdrawal from study; Current pregnancy; Withdrawal from study.